{
"id":"mk19_b_cv_t19",
"number":19,
"bookId":"cv",
"title":{
"__html":"Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"72b15c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 19. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t19"
}
]
},
"Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cf395",
"class":"col hd l",
"children":[
"Frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b02cd",
"class":"col hd l",
"children":[
"Type of AF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"455203",
"class":"col hd l",
"children":[
"Cautions and Dosing"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a56794",
"class":"cell txt l",
"children":[
"Warfarin (vitamin K antagonist)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41cfcf",
"class":"cell txt l",
"children":[
"Dose adjusted to INR"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"980ee7",
"class":"cell txt l",
"children":[
"Valvular",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" or nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"822c61",
"class":"cell txt l",
"children":[
"Avoid in pregnancy"
]
},
" ",
{
"type":"p",
"hlId":"9e43ba",
"class":"cell txt l",
"children":[
"Caution with idiopathic thrombocytopenic purpura, heparin-induced thrombocytopenia, liver disease, protein C or S deficiency"
]
},
" ",
{
"type":"p",
"hlId":"bd1f4e",
"class":"cell txt l",
"children":[
"Many drug and food interactions"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8315d3",
"class":"cell txt l",
"children":[
"Dabigatran (direct thrombin inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"053e2a",
"class":"cell txt l",
"children":[
"Twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"316743",
"class":"cell txt l",
"children":[
"Caution with use of P-glycoprotein inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"85ab38",
"class":"cell txt l",
"children":[
"Reduce dose with CrCl 15-30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61fdba",
"class":"cell txt l",
"children":[
"Rivaroxaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af8645",
"class":"cell txt l",
"children":[
"Once daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e07a77",
"class":"cell txt l",
"children":[
"Avoid with CrCl <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", moderate liver impairment, use of strong P-glycoprotein inhibitors, or use of strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"117a66",
"class":"cell txt l",
"children":[
"Reduce dose with CrCl 30-50 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1cf05d",
"class":"cell txt l",
"children":[
"Apixaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"053e2a",
"class":"cell txt l",
"children":[
"Twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e26dd6",
"class":"cell txt l",
"children":[
"Avoid with use of strong P-glycoprotein inhibitors or strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"9521f0",
"class":"cell txt l",
"children":[
"Reduce dose with two of the following criteria: creatinine level ≥1.5 mg/dL (133 μmol/L), age ≥80 y, or weight ≤60 kg (132 lb)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d94ad",
"class":"cell txt l",
"children":[
"Edoxaban (factor Xa inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af8645",
"class":"cell txt l",
"children":[
"Once daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab63f2",
"class":"cell txt l",
"children":[
"Nonvalvular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44117c",
"class":"cell txt l",
"children":[
"Avoid with use of strong cytochrome P-450 inducers and inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"b38f61",
"class":"cell txt l",
"children":[
"Avoid with CrCl >95 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" (reduced stroke prevention effectiveness). Reduce dose with CrCl 30-50 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", weight ≤60 kg (132 lb), or concomitant use of verapamil or quinidine (potent P-glycoprotein inhibitors)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AF = atrial fibrillation; CrCl = creatinine clearance."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Valvular atrial fibrillation refers to atrial fibrillation in the presence of moderate to severe mitral stenosis or mechanical valve prosthesis."
]
]
}